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Panel Discussion I: Evaluation and Management of Chronic 
Heart Failure 
PHILIP A. POOLEWILSON, MD, FRCP, FESC, MODERATOR, ROBERT J. CODY, MD, FACC, 
KALON K. L. HO, MD, CARL V. LEIER, MD, FACC, TERRENCE MONTAGUE, MD, 
MILTON PACKER, MD, FACC, BERTRAM PI’IT, MD, FACC, THOMAS W. SaMITH, MD, FACC, 
MARC D. THAMES, MD, FACC, SALIM YUSUF, MBBS, FRCP, DPHIL, FACC 
P. Peak-Wllsou: The purpose ofthis panel discussion is to 
assess the relevance of clinical trials to clinical practice. In
Britain, as in many other countries, we are concemed about 
the cost of health cam. To address this concern, our govem- 
q ent recently put forth a document toidentity where we 
should expend our health care resources. Tojustify expen- 
ditures, the document proposes that a disease meet hree 
criteria. 1) The disease should be common.2)Thedisease 
should be easy to detect and diagnose in the community. 
3) The disease should have au elfective therapy. If a disease 
meets all three criteria, then we have a health problem that 
should be treated aggressively and should attract resources. 
Heart failure is one of these diseases. 
Much ofwhat we lcnow about how to treat heart failure is 
based on the results of clinical trials, but are the patients 
enrolledinclinicaltriaistypicalofthepatientswithheart 
failureinthe community? To examine this question, we 
carriedastudyhtachaunscn lJedSreaofNolthLot&lthat 
is served by 1 ofthe 201 district general hospitals in Enghuid 
and W&s. Ofthe3O,ooOpersons~~bythehospitals,we 
found117patientswithheartfailure,aprevakncesomewhat 
hnverthanthatseenintheFraminghamStudy.Thatis 
luobablybecauseofthestrictde6nitionthatweusedinthe 
analysis. It is noteworthy t at he averape age ofthe patients 
inoursurveywas73,whereastheaverageagedthepatients 
etwlledin&nicaltrialsisapproximately6Oyears.This 
-on raises the question as to whether the patients 
evaluated in clinical trials are truly representative. Do others 
have a similar experience? If so, we might wonder how the 
results oftrials hould be applied to the community. 
T.wToaddressthisissue,wecreatedtheHeart 
Function Clllc, which serves acommunity-based popula 
rioninwesterncanadaTheaverageageofourpoltieatsis61 
yeanr,m~~the~~aFemenandmosthaveheart 
fhilurear;aresultdischemicheartdisease.~isa~y 
equaldistributionofpatientsinfim&nalclassesI,II,III 
andIV.Hence,thepatientsinourcommunityaresimilarto 
those enrolled in clinical trials. Furthemmre, when we Iwe 
examined prescribing patterns, we find that he med.i&~ 
~bygenemlpmcthionersinprivate~tice,faraway 
from the university center, are similar to those used by 
university-based physicians. Digitalis aud diuretics are pre 
scribed in61% and 66% of the patients, respectively. 
TheIIeartFunctionClinicisbasedonthteepriuciplesof 
therapy. 1)We will utilize fully all uuatments ofestablished 
benefit. 2)We will enroll as many ofourpatients as possil 
iuaclioicaltrialtoprovidethemwiththeintenseobsenu+ 
~~availableinarrial.3)Wewilldoeverythinginourpower 
to reduce hospitalktion and maintain these patients as 
outpatients. Prelimiuary data suggest that our approach 
reducesthelesgthofhospitalizationbyanav~of2days. 
TheHeartFunctionClinicalsopetmitsustopmvideoptimal 
the apyformorepatientsthaueverbefore.Ihavebeen 
disappointed over the years in the undenrtilizaticn of 
proved, e&&e therapy for marry w diseases. 
espcciallyforacutemyoca&linfar&n.Yettheutktion 
Ofae8iotensio_convzrtingenzYmeinbibaopsin~ 
with heart lkihue is 87%. That is much higher thau our 
utilizationofnitratesandbeta-blochersforacutemyocardia 
h&r&on in our hospital. 
P.PwIl!-w~Inamtrast,Ithinhthattheutikaknof 
. . sm-coavertingenxymeinhiiforheartlbilureis 
~lO%inBriteinandaboutl5%inFrance. 
ILIIoAunstruchbythesmallpercentaseofwomenin 
thesesurveys.DatalkomFmu@hamsuggestthatalthougb 
the incidence ofheart tkilure isless in women, the survival of
womenwithherytfailureisbetlertZlaa~d~.~ot, 
theoverallptevalenceofheart&ihneissimilarin~and 
women,0.7%innrenversus0.896inwomen0verallages 
and 2.4%versus 2.5% among those 245 years. 1 was 
wonderhtgifthepanelwouldcommentonwhywearesee@ 
sofewwomeniuclinicaltrials. 
S.Yns&Ithinltitisrelatedtotheklusioncrheriau~ 
in clinical trials. Most clinical trials exclude patknts without 
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systolic dysfunction, but by doing so, we are excluding many 
women and many patients with hypertension. In the first 
4,ooO patients enrolled inthe Digitis study, patients with a 
left ventricular ejection fraction >45% represented 0nIy 12% 
of the patients, but this cohort had a higher proportion f 
women, hypertensive patients and elderly patients. Hence, 
our entry criteria create a seIeftion bias. 
M, Packers The CONSENSUS study evaluated the oldest 
p&eat popuIation studied in a clinical trial; the average age 
of the patients was 71 years. Because jection fraction was 
not measured in the CONSENSUS study, we cannot be 
certain how many of the patients in the study had diastolic 
dysfunction of the elderly. Neverthdess, enalapril was ef- 
fective in the study. 
T. Smith: About 10 years ago, we cmductcd a survey 
(sponsored by the American Heart Association] ofpractice 
patterns in the treatment ofheart failure. We found that he 
use of established treatments was more prevalent among the 
spe&lis!s than the general practitioners, whereas internists 
&oyzd intermediate patterns of use (Hlatky et al. J Am Coil 
Cardiol 1986;8:966-70). 
MvI. Pa&r: Dr. Montague, the term, “heafl failure,” 
evokes uch a negative connotation among physicians, pa- 
tients and families that occasiontiy the term itself inhibits 
useful communication a d progress. By substituting the 
word “‘function” for the ward “failure,” you have reduced 
the negative impact of the disease on the patient-physician 
relation. 
P. P&-Wap(M: What advice would you currently give to 
doctors in the community with regard to heart failure? How 
should they make the diagnosis7 what set of investigations 
shouId they undertake? When should they refer patients? 
R. Ctiy: The first est I would recommend is a chest 
X-ray, followed by an echocardiw to evaluate the pres- 
ence or absence uf valvular disease. At our referral center, 
cardiac atheterizations arethen performed to etermine th  
presence or absence of cxxistent coronary artery disease, 
but this is not commonly done in the community, where 
clirkal criteria are utilized to distinguish ischemic from 
nonischemic heart disease. 
C. L&r: I swest o physicians that if they suspect heart 
failure in a given patient, hen they may want o refer the 
patient toa cardiologist who would etermine th need for a 
cardiac catheterization. Of all the patients with heart failure 
in the community who are referred to a cardiologist by a 
general internist or a family care physician, I suspect that no 
more than 50% undergo cardiac atheterization. 
P. Poole-W& How clear are you in your mind about 
the algorithm? It is easy to practice in the hospital setting 
where you have many resources, but arc you really clear on 
what you would advise a referring physician? 
T, Moattt8ne: I obtain an initial measurement of l& 
ventricular ejection fraction, usually by echocardiography or 
rad!ozuxlide v ntriculomhy, in alt patients with heart 
failure, and this is almost invariably followed by a wdiac 
catheterization. However, the nation may not be able to 
afford such an aggressive approach. From the view of 
cost-effectiveness, the best approach would include a chest 
x-ray, 833 eiectrocardiogram iEm:, a good diii~cs: evidua- 
tion and an echocardiogram. 
P. P&eWii: This is the appraach we are advocating 
in Britain, but it is not ammonly utilized. A chest X-ray and 
an ECG were prfixmed in at least 87% of the patients with 
heart failure, but an echocardiogram was perfomxd in only 
23% of the patients. 
T. hion-: At our institution we try to minimize the 
use of tests. Yet, the echocardiogram is very useful because 
it provides information about etiology and pathophysidqgy. 
C. Le& What tests are needed after the echocardio- 
gram? Many physicians have advocated the use of an 
exercise t st o assess functional capacity and to evaluate 
the efficacy oftreatment. The exercise t st is very helpful in 
grading the severity ofqmptoms, especially in patients who 
deny their symptoms. However, we can follow the effective- 
ness of therapy in most patients by simpIy monitoring 
symptoms and accompanying patients a  they walk around 
the room. With respect to additional testing, acardiologist 
should be asked to determine who should undergo cardiac 
catheterization o detect patients with operable, high grade 
coronary artery disease. 
P. Pa&W&HK If we followed your advice in my coun- 
try, we would be absolutely overwhelmed by the costs of 
medical care. We need to carefully select patients who need 
exercise t sting and cardiac catheterization. 
B, Fiti: Even in the United States, the approach advo- 
cated by Dr. L&r requires the availability ofsurgeons and 
angiopIasters who are willing to treat patients with severely 
impaired ventricular function. If such physicians are not 
available, there is no reason to conduct tests that will 
produce r volts hat will not be acted upon. 
P. mm: Let us now move to the diiult area of 
management. I assume that alI of the participants a  this 
conference would we that patients with established heart 
failure should receive diuretics and an angiotensin- 
convert@ enzyme inhibitor, and many would use digoxin. 
But how would the panel manage the patients with asymg 
tomatic kfYt ventricular dysfunction, cspe&By in the ps- 
ence of coronary artery disease? Such a patient could be 
treated with any of a combinatiotl f 10 dEerent drugs: 
aspirin, beta-blockers, calcium channel antagonists, anti- 
throtnbotic agents, anti-ischemic drugs, angiotensin- 
convert& enzp inhibitors, hypolipidemic dqs, digoxin, 
diurrtic~ntsorav~ator.WhsO~hshouldwewe? 
T. SmhL: I would use angiotensin-converting nzyme 
inhibitors in a patient who had marked left ventriculw 
systolic dysfunction even in the absence of symptoms, based 
on the results of the SOLVD prevention trial. 
P. PO&Wti Some of my colleagues would isagree 
with you. They would point out that the CONSENSUS II 
study showed no benefit of treatment with an angiotensin 
converting enzyme inhibitor and the benefits een in the 
SOLVD and SAVE trials are not apparent untii after 12 to 18 
months oftherapy. So why not simply observe the asymp- 
toma& pdent careMy u&ii he develqs symptoms? Once 
t% OsCGs, ~6u can plxe tie patient $2 ?#!4q!%~ @eat- 
ment. Such an approach would lx contcary to the proposals 
we have heard today, but it would consistent with Ihe results 
of clitical trials. 
B. Pitt: That m*t be true if you looked only at the 
mMfaljfy data, but you should also look at the prevention of
heart failure. IO the SOLVD prevention trial, angiotensin- 
conveding enzyme inhibition reduced the risk of developing 
heart failure from the time that therapy was initiated. Per- 
sonally, I would rather not develop heart failure or be 
hospitalized for heart failure. This is an important goal in 
addition to the reduction i  motiality. 
P. RmbWti But a doctor can prevent hospitalization 
by simply watching the patient closely. Many hospital&- 
Iions can be prevent4 by treat@ a patient aggressively as
an outpatient a  the first sign of clinical deterioration. 
S. Yti Dr. Poole-Wilson, it depends on the goals of 
therapy, If the prevention of cardiac dilation and heart 
failure is worthwhile, there is a good reason to heat patients 
prophylactically. 
